Teriperatide

TERIPARATIDE (PTH 1-34)

Bone Formation | Osteoblast Activity | Skeletal Health

Teriparatide is a synthetic form of the biologically active 1-34 amino-acid fragment of human parathyroid hormone (PTH). Unlike many osteoporosis therapies that primarily slow bone breakdown, teriparatide has an anabolic effect on bone, stimulating new bone formation when administered intermittently.

Teriparatide activates the PTH1 receptor, influencing calcium and phosphate metabolism while preferentially stimulating osteoblast activity over osteoclast activity with once-daily exposure.

Areas of Clinical Use & Research

• New bone formation

• Increased bone mineral density

• Osteoblast activity

• Osteoporosis and fracture-risk reduction

• Glucocorticoid-associated osteoporosis

• Skeletal remodeling and repair

• PTH1-receptor signaling

Established Clinical Dosage

The FDA-approved dosage of teriparatide is:

20 mcg subcutaneously once daily

Administration is into the thigh or abdominal region.

Treatment beyond two years during a patient's lifetime is generally considered only when the patient remains, or again becomes, at high risk for fracture.

Why Teriparatide Is Interesting

The timing of PTH exposure matters. Continuous PTH exposure can favor bone resorption, whereas brief intermittent exposure to teriparatide preferentially stimulates osteoblastic activity and new bone formation.

Clinical studies have demonstrated increases in bone mineral density, and teriparatide is approved for certain patients at high risk for osteoporotic fracture.

Storage

Commercial teriparatide pens are stored refrigerated at 2–8°C (36–46°F) and should not be frozen. Storage requirements for compounded, lyophilized, or other formulations may differ and should follow the specifications of the individual product.

Prescription medication. Dosage and treatment duration should be determined by an appropriately licensed healthcare professional.